CAMPHOR (SYNTHETIC)

US Approved OTC

First marketed in 1921

Details

Stereochemistry	RACEMIC
Molecular Formula	C10H16O
Molecular Weight	152.2334
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2

InChI

InChIKey=DSSYKIVIOFKYAU-XCBNKYQSSA-N

InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3/t7-,10+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H16O
Molecular Weight	152.2334
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=709 | http://www.webmd.com/vitamins-and-supplements/camphor-uses-amd-risks | http://www.sciencedirect.com/science/article/pii/B9780123864543007041

Camphor is a bicyclic monoterpene ketone found widely in plants, especially cinnamomum camphora. Topically, camphor is used to relieve pain. It has been used to treat warts, cold sores, hemorrhoids, and osteoarthritis. It has also been applied topically as an analgesic and an antipruritic. It has been used as a counterirritant, and to increase local blood flow. Camphor has frequently been used topically to treat respiratory tract diseases involving mucous membrane inflammation. It is sometimes used topically to treat cardiac symptoms. Camphor is also used topically as an eardrop, and for treating minor burns. In inhalation therapy, camphor is used as an antitussive. Orally, camphor is used as an expectorant, antiflatulent, and for treating respiratory tract diseases. Today, most camphor is synthetic. It is approved by the FDA as a topical antitussive. Camphor is produced synthetically from the oil of turpentine. It has been used for centuries for its medicinal features, in religious rituals, and in cooking. It is no longer used as pesticide. In 1982, the US Food and Drug Administration restricted commercial products intended for medicinal use to contain <11% camphor.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Transient receptor potential cation channel subfamily A member 1 37 Target ID: CHEMBL6007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897313	Antagonist 2737	1.26 mM [IC50]
Vanilloid receptor 49 Target ID: CHEMBL5102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16192383 \| https://www.ncbi.nlm.nih.gov/pubmed/25897313	Agonist 2637
Transient receptor potential cation channel subfamily V member 3 12 Target ID: CHEMBL5522 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16192383 \| https://www.ncbi.nlm.nih.gov/pubmed/25897313	Agonist 2637

Conditions

Condition	Modality	Highest Phase	Product
Pain 607 Sources: https://www.drugs.com/cdi/camphor-ointment.html http://www.webmd.com/vitamins-and-supplements/camphor-uses-amd-risks	Palliative	Approved 8307	Camphor ointment Approved Use Camphor ointment is used for: Treating pain and itching associated with minor skin irritations. Camphor ointment is a topical analgesic. It works by temporarily relieving itching and pain.
Cough 106 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c4d08cc6-e424-40ae-9c9b-5d5b1619377a&type=display http://www.webmd.com/vitamins-and-supplements/camphor-uses-amd-risks	Primary	Approved 8307	CAMPHOR, EUCALYPTUS OIL AND MENTHOL - camphor, eucalyptus oil and menthol ointment CVS Approved Use Uses - on chest and throat, temporarily relieves cough due to common cold - On muscles and joints, temporarily relieves minor aches and pains
Muscle pain 7 Sources: https://www.drugs.com/pro/tetramex-spray.html	Palliative	Approved 8307	Tetramex Spray Approved Use INDICATIONS AND USAGE: For temporary relief of minor aches and pains of the muscles and joints associated with simple backache, arthritis, strains, bruises and sprains.

C_max

Value	Dose	Co-administered	Analyte	Population
41 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342616/	374.4 mg single, topical dose: 374.4 mg route of administration: Topical experiment type: SINGLE co-administered: MENTHOL, UNSPECIFIED FORM	MENTHOL, UNSPECIFIED FORM	[NO STEREO] CAMPHOR, (-)-\|[NO STEREO] CAMPHOR (SYNTHETIC)\|[NO STEREO] CAMPHOR (NATURAL) plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
302 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342616/	374.4 mg single, topical dose: 374.4 mg route of administration: Topical experiment type: SINGLE co-administered: MENTHOL, UNSPECIFIED FORM	MENTHOL, UNSPECIFIED FORM	[NO STEREO] CAMPHOR, (-)-\|[NO STEREO] CAMPHOR (SYNTHETIC)\|[NO STEREO] CAMPHOR (NATURAL) plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342616/	374.4 mg single, topical dose: 374.4 mg route of administration: Topical experiment type: SINGLE co-administered: MENTHOL, UNSPECIFIED FORM	MENTHOL, UNSPECIFIED FORM	[NO STEREO] CAMPHOR, (-)-\|[NO STEREO] CAMPHOR (SYNTHETIC)\|[NO STEREO] CAMPHOR (NATURAL) plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P003PPK
AK Scientific	5739AF
AbovChem LLC	HY-B1173
Acros Organics	10819
Acros Organics	16464
Acros Organics	22784
Alfa Chemistry	A10708
Alfa Chemistry	A10936
Alfa Chemistry	ACM76222
BLD Pharm	BD123522
BOC Sciences	21368-68-3
BOC Sciences	76-22-2
Bide Pharmatech	BD123522
BioSynth	Q-200785
BioSynth	W-109539
BioSynth	W-110530
Chem Scene	CS-4779
ChemShuttle	141803
Chemspace	CSC000759907
Combi-Blocks	QE-0007
Enamine	BBV-175078
Enamine	EN300-84949
Fluorochem	94195
Fluorochem	94196
Frontier Scientific Services	500030259
HongKong Chemhere	SCA29141
IBScreen	BB_NC-00198
IBScreen	BB_NC-02664
IBScreen	STOCK1N-66758
Indofine	25342
Lab Network	LN00241548
MedChem Express	HY-B1173
MolPort	MolPort-001-793-333
Molnova	M14559
Oakwood	94195
Sigma Aldrich	02070595\|SIAL
Sigma Aldrich	05-1200\|SAJ
Sigma Aldrich	20506\|SIAL
Sigma Aldrich	21300\|SIAL
Sigma Aldrich	W223023
TargetMol	T0882
Tetrahedron	TS10230
TimTec	SBB012351
TimTec	ST069333
Toronto Research Chemicals	C165800
W&J PharmaChem	50C271904
ZINC	ZINC000000967520	http://zinc15.docking.org/substances/ZINC000000967520
eMolecules	482330
mcule	MCULE-4378124154
mcule	MCULE-8475137009

PubMed

Title	Date	PubMed
Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.	2000 Oct 13	10896673
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.	2001	11291833
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.	2001	11244327
Treatment of extensive stage small cell lung cancer.	2001	11224990
Irinotecan: a new agent comes of age.	2001	11161229
Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.	2001	11089242
Assaying drug-induced apoptosis.	2001	11089236
Drug toxicity in E. coli cells expressing human topoisomerase I.	2001	11089232
Analysis of cleavage complexes using reactive inhibitor derivatives.	2001	11089223
Flow cytometric fluorescence lifetime measurements.	2001	11060839
A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide.	2001 Apr	11279278
Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.	2001 Apr	11268051
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.	2001 Apr	11259359
Monochloramine inhibits etoposide-induced apoptosis with an increase in DNA aberration.	2001 Apr 15	11295536
A link between apoptosis and degree of phosphorylation of high mobility group A1a protein in leukemic cells.	2001 Apr 6	11145960
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.	2001 Feb	11273589
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.	2001 Feb	11207057
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.	2001 Feb 9	11162657
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.	2001 Jan	11272292
A novel genetic screen identifies checkpoint-defective alleles of Schizosaccharomyces pombe chk1.	2001 Jan	11270571
Irinotecan: summary and future directions.	2001 Jan	11221021
Irinotecan in small-cell lung cancer: the US experience.	2001 Jan	11221015
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.	2001 Jan	11205920
Pharmacological determinants of 9-aminocamptothecin cytotoxicity.	2001 Jan	11205905
Apoptosis enhancement by the HIV-1 Nef protein.	2001 Jan 1	11123279
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.	2001 Jan 25	11191660
[A case of AFP-producing gastric cancer responding to low-dose CPT-11 and low-dose cisplatin combination chemotherapy].	2001 Mar	11265410
Topoisomerase I targeting agents in small-cell lung cancer.	2001 Mar	11177750
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.	2001 Mar 1	11280753
Irinotecan in the treatment of colorectal cancer: clinical overview.	2001 Mar 1	11230497
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.	2001 Mar 12	11245909

Patents

Sample Use Guides

In Vivo Use Guide

Dosing: Adult Cough: Inhalation: Inhale via vaporizer up to 3 times per day. Pain: Topical cream: Apply to affected area up to 4 times per day for 2 weeks. For maximum benefit, use daily for at least 2 weeks and continue to use daily as needed thereafter. Pruritus/Pain: Topical gel: Apply to affected area up to 3 to 4 times per day.

Route of Administration: Topical

In Vitro Use Guide

1 mM camphor partially inhibited the AITC (20 uM)-induced hTRPA1 current in HEK293T cells expressing hTRPA1.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 22:31:11 UTC 2022` Edited by `admin` on `Fri Dec 16 22:31:11 UTC 2022`
Record UNII	5TJD82A1ET
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CAMPHOR (SYNTHETIC)

Common Name

English

CAMPHOR, DL-

Common Name

English

2-BORNANONE

Systematic Name

English

DL-CAMPHOR

Common Name

English

CAMPHOR, RACEMIC

Common Name

English

(±)-CAMPHOR

Systematic Name

English

CAMPHOR, (±)-

Systematic Name

English

1,7,7-TRIMETHYLBICYCLO(2.2.1)HEPTAN-2-ONE

Systematic Name

English

FEMA NO. 4513

Code

English

(1RS,4RS)-1,7,7-TRIMETHYLBICYCLO(2.2.1)HEPTAN-2-ONE

Systematic Name

English

BICYCLO(2.2.1)HEPTANE-2-ONE, 1,7,7-TRIMETHYL-

Systematic Name

English

GUM CAMPHOR

Common Name

English

CAMPHOR, RACEMIC [EP MONOGRAPH]

Common Name

English

2-CAMPHANONE

Systematic Name

English

DL-CAMPHOR [JAN]

Common Name

English

Camphor [WHO-DD]

Common Name

English

SYNTHETIC CAMPHOR

Common Name

English

CAMPHOR [MI]

Common Name

English

CAMPHOR [HSDB]

Common Name

English

CAMPHOR [INCI]

Common Name

English

Code System Code Type Description

DAILYMED

5TJD82A1ET